Kidney StonesNCT07336485
Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Renal Stones
A study testing Furosemide in people with Kidney Stones, run by Ain Shams University at 1 site in Egypt.
Trial summary
This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved stone clearance in patients with renal stones measuring up to 30 millimeters. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Stones
- What is being tested?
- Furosemide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2026to 1 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients aged 18 years or older.
- Patients who underwent flexible ureteroscopy for renal stones measuring 30 millimeters or less.
Who cannot join
- Patients with active urinary tract infection.
- Patients with a history of previous open renal surgery or renal trauma.
- Patients with contraindications to anesthesia, such as severe cardiac disease, uncontrolled diabetes mellitus, or severe coagulation disorder.
- Patients with severe renal impairment, defined as an estimated glomerular filtration rate less than 30 milliliters per minute per 1.73 square meters.
- Known Ureteric stricture and pelvi-ureteric junction obstruction
- Patients with a single kidney.
- Patients with contraindications to furosemide administration.
- Patients with congenital renal anomalies.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Ain Shams University Hospitals (Urology Department)
Cairo, Cairo Governorate, 11511
About this study
This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved stone clearance in patients with renal stones measuring up to 30 millimeters. Adult patients undergoing flexible ureteroscopy were randomized into two parallel groups: an experimental group that received intravenous furosemide during the procedure and a control group that received standard perioperative and postoperative care without furosemide. Residual stone fragments were assessed using low-dose non-contrast computed tomography on postoperative day 1 and at 6 weeks after the procedure. The primary outcome was the proportion of patients with residual stone fragments greater than 2 millimeters on postoperative day 1. Secondary outcomes included the proportion of patients with residual stone fragments greater than 2 millimeters at 6 weeks, operative time, postoperative complications, and the need for auxiliary treatment for clinically significant residual stones.
- Conditions
- Kidney Stones
- Being tested
- Furosemide, Standard Care After Flexible Ureteroscopy Without Furosemide
- Keywords
- Kidney stones, renal calculi, nephrolithiasis, flexible ureteroscopy, ureteroscopy, laser lithotripsy, residual stone fragments, stone-free rate, forced diuresis, furosemide, non-contrast computed tomography
- Medical subject headings
- Kidney Calculi, Nephrolithiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FurosemideDrug
Intravenous furosemide was administered as a total dose of 40 milligrams during the procedure, divided into 20 milligrams given 5 minutes after induction of anesthesia and 20 milligrams given 30 minutes after the start of the procedure.
Standard Care After Flexible Ureteroscopy Without FurosemideOther
Participants received standard perioperative and postoperative management after flexible ureteroscopy without administration of furosemide or any other diuretic medication.
| Study group | Role | What they receive |
|---|---|---|
| Furosemide-Assisted Forced Diuresis During Flexible Ureteroscopy | Experimental | During flexible ureteroscopy, participants received intravenous furosemide 40 milligrams total, divided into 20 milligrams administered 5 minutes after induction of anesthesia and 20 milligrams administered 30 minutes after the start of the procedure. Receives: Drug: Furosemide |
| Standard Care During Flexible Ureteroscopy Without Furosemide | Active comparator | Participants underwent flexible ureteroscopy and received standard perioperative and postoperative care without receiving intravenous furosemide or any other diuretic medication. Receives: Other: Standard Care After Flexible Ureteroscopy Without Furosemide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with residual stone fragments greater than 2 mm
Residual stone fragments were assessed using low-dose non-contrast computed tomography (CT) performed on postoperative day 1. The outcome was reported as the proportion of patients with one or more residual renal stone fragments measuring greater than 2 mm.
Measured: Postoperative day 1 after flexible ureteroscopy
Secondary outcomes (4)
Operative time
Operative time was calculated from insertion of the ureteroscope into the urethra until completion of ureteral stent placement.
Measured: During procedure
Postoperative urinary tract infection
Postoperative urinary tract infection was assessed within seven days after the procedure using fever with urinary symptoms and or a positive urine culture with significant bacteriuria.
Measured: Within 7 days post-procedure
Need for auxiliary treatment for clinically significant residual stones
The need for auxiliary treatment for clinically significant residual stones was recorded, including extracorporeal shock wave lithotripsy or repeat ureteroscopy.
Measured: Up to 6 weeks after flexible ureteroscopy
Proportion of patients with residual stone fragments greater than 2 mm at 6 weeks
Residual stone fragments were assessed using low-dose non-contrast computed tomography (CT) performed 6 weeks after flexible ureteroscopy. The outcome was reported as the proportion of patients with one or more residual renal stone fragments measuring greater than 2 mm.
Measured: 6 weeks after flexible ureteroscopy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start1 Jan 2026
- Primary completion1 Jul 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney StonesStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly assigned in a one-to-one ratio to receive either intravenous furosemide-assisted forced diuresis during flexible ureteroscopy or standard care without furosemide during flexible ureteroscopy.
- Masking
- None (open label)
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Nasser Karamany Mokhat, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07336485
- Sponsor's protocol ID
- FMASU MS 686/2025
- Status last verified
- Aug 2026
- First submitted
- 16 Dec 2025
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Renal Stones
- ClinicalTrials.gov ID
- NCT07336485
- Acronym / sponsor ID
- FMASU MS 686/2025
- Conditions
- Kidney Stones
- Keywords
- Kidney stones, renal calculi, nephrolithiasis, flexible ureteroscopy, ureteroscopy, laser lithotripsy, residual stone fragments, stone-free rate
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 1 Jul 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved stone clearance in patients with renal stones measuring up to 30 millimeters. Adult patients undergoing flexible ureteroscopy were randomized into two parallel groups: an experimental group that received intravenous furosemide during the procedure and a control group that received standard perioperative and postoperative care without furosemide. Residual stone fragments were assessed using low-dose non-contrast computed tomography on postoperative day 1 and at 6 weeks after the procedure. The primary outcome was the proportion of patients with residual stone fragments greater than 2 millimeters on postoperative day 1. Secondary outcomes included the proportion of patients with residual stone fragments greater than 2 millimeters at 6 weeks, operative time, postoperative complications, and the need for auxiliary treatment for clinically significant residual stones.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants were randomly assigned in a one-to-one ratio to receive either intravenous furosemide-assisted forced diuresis during flexible ureteroscopy or standard care without furosemide during flexible ureteroscopy.
| Arm | Type | Receives |
|---|---|---|
| Furosemide-Assisted Forced Diuresis During Flexible Ureteroscopy | Experimental | Drug: FurosemideDuring flexible ureteroscopy, participants received intravenous furosemide 40 milligrams total, divided into 20 milligrams administered 5 minutes after induction of anesthesia and 20 milligrams administered 30 minutes after the start of the procedure. |
| Standard Care During Flexible Ureteroscopy Without Furosemide | Active comparator | Other: Standard Care After Flexible Ureteroscopy Without FurosemideParticipants underwent flexible ureteroscopy and received standard perioperative and postoperative care without receiving intravenous furosemide or any other diuretic medication. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult patients aged 18 years or older.
- Patients who underwent flexible ureteroscopy for renal stones measuring 30 millimeters or less.
Key exclusion criteria (8 listed)
- Patients with active urinary tract infection.
- Patients with a history of previous open renal surgery or renal trauma.
- Patients with contraindications to anesthesia, such as severe cardiac disease, uncontrolled diabetes mellitus, or severe coagulation disorder.
- Patients with severe renal impairment, defined as an estimated glomerular filtration rate less than 30 milliliters per minute per 1.73 square meters.
- Known Ureteric stricture and pelvi-ureteric junction obstruction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FurosemideIntravenous furosemide was administered as a total dose of 40 milligrams during the procedure, divided into 20 milligrams given 5 minutes after induction of anesthesia and 20 milligrams given 30 minutes after the start of the procedure. | Drug | Furosemide-Assisted Forced Diuresis During Flexible Ureteroscopy |
| Standard Care After Flexible Ureteroscopy Without FurosemideParticipants received standard perioperative and postoperative management after flexible ureteroscopy without administration of furosemide or any other diuretic medication. | Other | Standard Care During Flexible Ureteroscopy Without Furosemide |
Primary outcome
Proportion of patients with residual stone fragments greater than 2 mm
Time frame: Postoperative day 1 after flexible ureteroscopy
Residual stone fragments were assessed using low-dose non-contrast computed tomography (CT) performed on postoperative day 1. The outcome was reported as the proportion of patients with one or more residual renal stone fragments measuring greater than 2 mm.
4 secondary outcomes
Operative time
Time frame: During procedure
Postoperative urinary tract infection
Time frame: Within 7 days post-procedure
Need for auxiliary treatment for clinically significant residual stones
Time frame: Up to 6 weeks after flexible ureteroscopy
Proportion of patients with residual stone fragments greater than 2 mm at 6 weeks
Time frame: 6 weeks after flexible ureteroscopy
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Kidney Stones
Not yet recruiting
Automated Versus Manual Irrigation During Flexible Ureteroscopy
Renal Stone Disease
Not yet recruiting
Optimal Intrarenal Pressure During Flexible Ureteroscopy
Renal Stone Disease
RecruitingObservational study
Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study
Urolithiasis, Stones, Kidney
Not yet recruiting
Intertransverse Process Block Versus Erector Spinae Plane Block for Postoperative Analgesia After Percutaneous Nephrolithotomy
Kidney Stones, Urolithiasis, Hypocitraturia, Pain, Postoperative
Not yet recruiting
Comparison of Smart Pressure-Controlled Flexible Ureteroscopy and Flexible Suction Ureteral Access Sheath-Assisted Flexible Ureteroscopy for 2-3 cm Renal Stones
Kidney Stones
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Furosemide in people with Kidney Stones, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with residual stone fragments greater than 2 mm (time frame: Postoperative day 1 after flexible ureteroscopy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.